ADMA BIOLOGICS’s Sentiment

“Big money sentiment for ADMA BIOLOGICS (NASDAQ:ADMA) in Q4 2018 decreased to 0.85, according to SEC.gov filings. That’s down -0.95, from 2018Q3’s 1.8. 22 hedge funds increased and opened new holdings, while 26 sold and decreased positions in ADMA BIOLOGICS so the sentiment dived. Funds own 23.97 million shares, down from 25.12 million shares in 2018Q3. Funds holding ADMA BIOLOGICS in top 10 decreased from 2 to 1 for a decrease of 1. 9 Investors Sold All; 17 Reduced Holdings; 15 increased stakes while 7 hedge funds bought stakes.

Significant ADMA BIOLOGICS Shareholders

Aisling Capital Llc owns 3.61 million shares in ADMA BIOLOGICS as of Q4 2018. As of Q4 2018, 4.23 million shares of ADMA BIOLOGICS are owned by Broadfin Capital Llc. Morgens Waterfall Vintiadis & Co Inc reported 400,000 shares. Consonance Capital Management Lp revealed 4.59 million shares position in ADMA BIOLOGICS. The New York-based fund Perceptive Advisors Llc looks positive on ADMA BIOLOGICS, possessing 6.52 million shares.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases.The firm is valued at $180.77 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease.Currently it has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

ADMA reached $3.9 during the last trading session after $0.03 change.ADMA Biologics, Inc. has volume of 49,228 shares. Since March 13, 2018 ADMA has risen 10.36% and is uptrending. The stock outperformed the S&P 500 by 5.99%.

Aisling Capital Llc invested 2.44% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Dimensional Fund Advsr Limited Partnership accumulated 14,127 shs. 26,871 were accumulated by Raymond James And Assocs. Tower Ltd Liability (Trc) accumulated 0% or 4,117 shs. Bancorp Of New York Mellon has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Fin Architects Inc holds 18,500 shs. Blackrock stated it has 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Cambridge Invest Rech Advisors reported 10,000 shs stake. Intl Gp has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 12,735 shs. State Of Wisconsin Invest Board, Wisconsin-based fund reported 20,000 shs. Moreover, Meeder Asset Management Inc has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 829 shs. Moreover, Gru One Trading Limited Partnership has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA). Broadfin Cap Limited Liability Corp holds 1.33% or 4.23M shs in its capital. Vanguard Group Inc reported 0% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). 683 Cap Limited Liability Corp reported 805,000 shs.

ADMA Biologics, Inc. (NASDAQ:ADMA) Ratings Coverage

In total 2 analysts cover ADMA Biologics (NASDAQ:ADMA). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:ADMA)’s analyst reports since October 12, 2018 according to StockzIntelligence Inc. On Thursday, February 21 H.C. Wainwright maintained ADMA Biologics, Inc. (NASDAQ:ADMA) rating. H.C. Wainwright has “Buy” rating and $10 target. On Friday, October 12 the company was maintained by Raymond James. On Thursday, February 7 the stock of ADMA Biologics, Inc. (NASDAQ:ADMA) has “Buy” rating given by H.C. Wainwright.

For more ADMA Biologics, Inc. (NASDAQ:ADMA) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Stellar Biotechnologies and Alphatec Holdings among healthcare gainers; Nektar Therapeutics and Molina Healthcare among losers – Seeking Alpha” brought out on February 12, 2019, “Pernix Therapeutics leads healthcare gainers; Natus Medical and Cambrex among losers – Seeking Alpha” on February 13, 2019, “ADMA Biologics to Present at Upcoming Investor Conferences – Nasdaq” with a publish date: February 25, 2019, “ADMA Biologics: Finish Line Ahead? – Seeking Alpha” and the last “ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors – GlobeNewswire” with publication date: February 12, 2019.